Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
36 studies found for:    z4099
Show Display Options
Rank Status Study
1 Active, not recruiting Surgery With or Without Internal Radiation Therapy Compared With Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Stage I Non-Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Procedure: therapeutic conventional surgery;   Radiation: iodine I 125;   Radiation: stereotactic body radiation therapy
2 Completed The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
Condition: Parkinson's Disease
Intervention: Drug: E2007
3 Recruiting Study Of Diabetic Nephropathy With Atrasentan
Condition: Diabetic Nephropathy
Interventions: Drug: Atrasentan;   Drug: Placebo
4 Active, not recruiting Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination With Peginterferon α-2a vs Standard of Care Tenofovir Disoproxil Fumarate Monotherapy or Peginterferon α-2a Monotherapy for 48 Weeks in Chronic Hepatitis B(CHB).
Condition: Chronic Hepatitis B
Interventions: Drug: TDF;   Drug: PEG
5 Available INC424 for Patients With Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis
Conditions: Myelofibrosis (PMF);   Post Polycythemia Myelofibrosis (PPV MF);   Post-essential Thrombocythemia Myelofibrosis (PET-MF);   Myelofibrosis;   Post Polycythemia Myelofibrosis;   Post-essential Thrombocythemia Myelofibrosis
Intervention: Drug: INC424
6 Recruiting A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)
Condition: Metastatic Breast Cancer
Interventions: Biological: PF-05280014;   Drug: Paclitaxel;   Biological: Herceptin®
7 Recruiting Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)
Condition: Stroke
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin (Acetylsalicylic acid, BAY1019036);   Other: Rivaroxaban-Placebo;   Other: Aspirin-Placebo
8 Completed
Has Results
"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk
Condition: Neoplasms, Prostate
Interventions: Drug: Dutasteride;   Drug: Placebo
9 Terminated GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: GSK1605786A;   Drug: Placebo
10 Terminated Open-Label Extension Study of GSK1605786A
Condition: Crohn's Disease
Intervention: Drug: GSK1605786A
11 Recruiting A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)
Condition: Follicular Lymphoma
Interventions: Biological: PF-05280586;   Biological: MabThera®
12 Completed Evaluation of Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.
Condition: Seizure Disorder, Partial
Intervention: Drug: Pregabalin
13 Completed
Has Results
Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients
Condition: Venous Thromboembolism
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Enoxaparin;   Drug: Rivaroxaban placebo;   Drug: Enoxaparin placebo
14 Recruiting Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction
Condition: Heart Failure With Preserved Ejection Fraction
Interventions: Drug: LCZ696;   Drug: Valsartan
15 Completed
Has Results
Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Regorafenib (Stivarga, BAY73-4506);   Drug: Placebo;   Other: Best Supportive Care (BSC)
16 Completed
Has Results
Pre-Mix Insulin Lispro Treatment for Type 2 Diabetes Patients Who Consume a Light Breakfast
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Insulin Glargine;   Drug: Insulin Lispro Premix (mid-mixture and low-mixture)
17 Completed
Has Results
Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Exenatide (AC2993);   Drug: Insulin glargine
18 Recruiting American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis
Conditions: Wegener's Granulomatosis;   Microscopic Polyangiitis;   Churg Strauss Syndrome;   Polyarteritis Nodosa;   Giant Cell Arteritis;   Takayasu Arteritis
Intervention:
19 Completed REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy
Condition: Hepatitis C, Chronic
Interventions: Drug: Ribavirin;   Drug: peginterferon alfa-2a [Pegasys]
20 Recruiting A Study of RoActemra/Actemra (Tocilizumab) in Patients With Giant Cell Arteritis
Condition: Giant Cell Arteritis
Interventions: Drug: prednisone;   Drug: prednisone placebo;   Drug: tocilizumab [RoActemra/Actemra];   Drug: tocilizumab placebo

   Previous Page Studies Shown (1-20) Next Page (21-36) Show next page of results    Last Page
Indicates status has not been verified in more than two years